Literature DB >> 26176392

Oral Propranolol for Infantile Hemangioma.

Christine Léauté-Labrèze, Jean-Jacques Voisard, Nicholas Moore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176392     DOI： 10.1056/NEJMc1503811

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.

Authors:  Virginia Albiñana; Karina Villar Gómez de Las Heras; Gemma Serrano-Heras; Tomás Segura; Ana Belén Perona-Moratalla; Mercedes Mota-Pérez; José María de Campos; Luisa María Botella
Journal:  Orphanet J Rare Dis       Date:  2015-09-22       Impact factor: 4.123

2.  Propranolol therapy for infantile hemangioma: our experience.

Authors:  Ling Zhang; Hai-Wei Wu; Weien Yuan; Jia-Wei Zheng
Journal:  Drug Des Devel Ther       Date:  2017-05-08       Impact factor: 4.162

3.  Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome.

Authors:  Arun Mohanan Ainipully; Sarath Kumar Narayanan; Arun Preeth Vazhiyodan; Prathap Somnath
Journal:  J Indian Assoc Pediatr Surg       Date:  2019 Jul-Sep

4.  R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma.

Authors:  Jeroen Overman; Frank Fontaine; Jill Wylie-Sears; Mehdi Moustaqil; Lan Huang; Marie Meurer; Ivy Kim Chiang; Emmanuelle Lesieur; Jatin Patel; Johannes Zuegg; Eddy Pasquier; Emma Sierecki; Yann Gambin; Mohamed Hamdan; Kiarash Khosrotehrani; Gregor Andelfinger; Joyce Bischoff; Mathias Francois
Journal:  Elife       Date:  2019-07-30       Impact factor: 8.140
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.